BioAge Labs, Inc. (BIOA) AI Stock Analysis

• Market Cap: $267.80M
• Dividend Yield: N/A
• Average Volume (3M): 196.83K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.64
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 62
• Sector: Healthcare
• Sector Strength: 45
• Industry: Biotechnology
• EPS (TTM): -0.56
• Shares Outstanding: 35,850,037
• 10 Day Avg. Volume: 197,907
• 30 Day Avg. Volume: 196,830
• PEG Ratio: 0.04
• Price to Book (P/B): 0.19
• Price to Sales (P/S): 0.00
• P/FCF Ratio: -1.20
• Enterprise Value/Market Cap: -0.52
• Enterprise Value/Revenue: -23.74
• Enterprise Value/Gross Profit: -23.74
• Enterprise Value/Ebitda: 1.88
• 1Y Price Target: $10.00
• Price Target Upside: 5.37% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 3
• EPS Forecast (FY): N/A
• Revenue Forecast (FY): N/A

• Rating: 33 Underperform
• Price Target: ―

BioAge Labs, Inc. is facing critical financial difficulties, characterized by no revenue generation, increasing losses, and dependence on external financing. The technical indicators suggest a bearish trend, and the lack of valuation metrics such as P/E ratio and dividend yield complicates valuation. These factors collectively reflect a weak overall stock performance.

Positive Factors

Improved Balance Sheet

The improvement in the debt-to-equity position indicates a stronger financial foundation, enhancing the company's ability to secure future financing and invest in growth opportunities.

Strategic Partnerships

Strategic partnerships provide a pathway for shared development costs and potential profits, which can enhance financial stability and accelerate product development.

Proprietary Platform

The proprietary platform offers a competitive advantage by enabling the development of innovative therapies, potentially leading to breakthroughs in age-related disease treatments.

Negative Factors

No Revenue Generation

The lack of revenue generation is a critical concern, as it limits the company's ability to achieve profitability and sustain operations without external funding.

Increasing Losses

Rising losses indicate operational inefficiencies and financial strain, which could hinder long-term growth and sustainability if not addressed.

Reliance on External Financing

Dependence on external financing poses sustainability risks, as it may lead to dilution of equity and increased financial obligations, impacting future growth potential.

BioAge Labs, Inc. Business Overview & Revenue Model

Company Description

BioAge Labs, Inc. (BIOA) is a biotechnology company focused on developing innovative therapies aimed at extending healthy human lifespan by targeting the molecular pathways associated with aging. The company leverages its proprietary platform to identify and validate drug targets that can modulate key biological processes involved in aging. BioAge's core products include a pipeline of therapeutic candidates designed to treat age-related diseases and improve healthspan.

How the Company Makes Money

BioAge Labs, Inc. generates revenue primarily through partnerships and collaborations with pharmaceutical companies, as well as through research grants and funding. The company engages in strategic alliances to co-develop and commercialize its therapeutic candidates, which allows it to share development costs and potential profits. Additionally, BioAge may receive milestone payments and royalties from its partners as its drug candidates progress through clinical trials and, if successful, reach the market. The company may also rely on venture capital investments and public or private offerings to fund its research and development activities.

BioAge Labs, Inc. Financial Statement Overview

Summary

BioAge Labs, Inc. faces significant financial challenges, with no revenue generation and increasing losses impacting profitability. While the balance sheet has improved due to recent financing activities, the company's reliance on external funds and negative cash flows suggest ongoing financial instability. The company needs to address its revenue generation capabilities to improve its financial health.

Income Statement

BioAge Labs, Inc. has not generated any revenue over the past three years, impacting its ability to achieve positive profit margins. The company is experiencing increasing losses, as reflected in the negative EBIT and net income figures. This lack of revenue generation and increasing losses are significant concerns for the company's financial health.

Balance Sheet

The company's debt-to-equity position has improved significantly, transitioning from negative equity to a positive equity position in 2024, driven by increased financing activities. Despite this improvement, the company still carries some debt, which poses a risk. The equity ratio has improved to 90%, indicating a stronger balance sheet, but the company's reliance on external financing remains a concern.

Cash Flow

BioAge Labs, Inc. has been raising substantial funds, as seen from the positive financing cash flow. However, the company is still burning cash, with negative operating and free cash flows. The free cash flow growth rate remains negative, indicating ongoing operational cash challenges. The company's ability to sustain operations relies heavily on external financing, posing sustainability risks.

Breakdown	TTM	Dec 2024	Dec 2023	Dec 2022
Income Statement
Total Revenue	5.92M	0.00	0.00	0.00
Gross Profit	5.92M	0.00	0.00	0.00
EBITDA	-74.68M	-68.58M	-55.90M	-39.35M
Net Income	-75.79M	-71.11M	-63.85M	-39.72M
Balance Sheet
Total Assets	305.09M	358.23M	25.92M	28.43M
Cash, Cash Equivalents and Short-Term Investments	285.78M	354.35M	21.64M	27.64M
Total Debt	7.13M	8.70M	53.25M	2.47M
Total Liabilities	27.63M	35.11M	199.32M	140.99M
Stockholders Equity	277.46M	323.13M	-173.40M	-112.56M
Cash Flow
Free Cash Flow	-59.15M	-51.89M	-37.53M	-36.28M
Operating Cash Flow	-58.51M	-51.52M	-37.36M	-36.18M
Investing Cash Flow	-80.81M	-366.00K	-266.00K	-103.00K
Financing Cash Flow	20.36M	381.20M	34.94M	2.50M

BioAge Labs, Inc. Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
DERM	57 Neutral	$218.99M	―	-47.05%	―	2.82%	60.26%
IRWD	54 Neutral	$311.87M	―	―	―	-10.42%	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
LFCR	48 Neutral	$254.02M	-5.20	―	―	0.47%	-430.88%
IXHL	39 Underperform	$124.71M	―	-114.52%	―	-86.05%	24.17%
BIOA	33 Underperform	$267.80M	-3.34	-25.64%	―	―	―